MEDISTIM ASA (MEDI.OL) Fundamental Analysis & Valuation

OSL:MEDI • NO0010159684

Current stock price

234 NOK
+2 (+0.86%)
Last:

This MEDI.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. MEDI.OL Profitability Analysis

1.1 Basic Checks

  • MEDI had positive earnings in the past year.
  • In the past year MEDI had a positive cash flow from operations.
  • MEDI had positive earnings in each of the past 5 years.
  • In the past 5 years MEDI always reported a positive cash flow from operatings.
MEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFMEDI.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 24.10%, MEDI belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 33.99%, MEDI belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
  • The Return On Invested Capital of MEDI (29.26%) is better than 98.41% of its industry peers.
Industry RankSector Rank
ROA 24.1%
ROE 33.99%
ROIC 29.26%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDI.OL Yearly ROA, ROE, ROICMEDI.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of MEDI (22.75%) is better than 96.83% of its industry peers.
  • In the last couple of years the Profit Margin of MEDI has grown nicely.
  • MEDI has a better Operating Margin (28.04%) than 96.83% of its industry peers.
  • MEDI's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of MEDI (81.68%) is better than 93.65% of its industry peers.
  • In the last couple of years the Gross Margin of MEDI has remained more or less at the same level.
Industry RankSector Rank
OM 28.04%
PM (TTM) 22.75%
GM 81.68%
OM growth 3Y-0.79%
OM growth 5Y1.29%
PM growth 3Y-0.6%
PM growth 5Y3.55%
GM growth 3Y1.4%
GM growth 5Y0.69%
MEDI.OL Yearly Profit, Operating, Gross MarginsMEDI.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MEDI.OL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDI is creating value.
  • MEDI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEDI.OL Yearly Shares OutstandingMEDI.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDI.OL Yearly Total Debt VS Total AssetsMEDI.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • MEDI has a debt to FCF ratio of 0.20. This is a very positive value and a sign of high solvency as it would only need 0.20 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.20, MEDI belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that MEDI is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.08, MEDI belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.2
Altman-Z N/A
ROIC/WACC3.42
WACC8.55%
MEDI.OL Yearly LT Debt VS Equity VS FCFMEDI.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MEDI has a Current Ratio of 3.34. This indicates that MEDI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MEDI (3.34) is better than 87.30% of its industry peers.
  • MEDI has a Quick Ratio of 2.21. This indicates that MEDI is financially healthy and has no problem in meeting its short term obligations.
  • MEDI has a Quick ratio of 2.21. This is amongst the best in the industry. MEDI outperforms 84.13% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 2.21
MEDI.OL Yearly Current Assets VS Current LiabilitesMEDI.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MEDI.OL Growth Analysis

3.1 Past

  • MEDI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.62%, which is quite impressive.
  • MEDI shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.02% yearly.
  • Looking at the last year, MEDI shows a very strong growth in Revenue. The Revenue has grown by 24.38%.
  • Measured over the past years, MEDI shows a quite strong growth in Revenue. The Revenue has been growing by 14.02% on average per year.
EPS 1Y (TTM)53.62%
EPS 3Y11.79%
EPS 5Y18.02%
EPS Q2Q%79.18%
Revenue 1Y (TTM)24.38%
Revenue growth 3Y12.46%
Revenue growth 5Y14.02%
Sales Q2Q%20.61%

3.2 Future

  • Based on estimates for the next years, MEDI will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.81% on average per year.
  • Based on estimates for the next years, MEDI will show a quite strong growth in Revenue. The Revenue will grow by 11.61% on average per year.
EPS Next Y9.34%
EPS Next 2Y10.32%
EPS Next 3Y10.81%
EPS Next 5YN/A
Revenue Next Year18.2%
Revenue Next 2Y13.27%
Revenue Next 3Y11.61%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MEDI.OL Yearly Revenue VS EstimatesMEDI.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
MEDI.OL Yearly EPS VS EstimatesMEDI.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

3

4. MEDI.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.87 indicates a quite expensive valuation of MEDI.
  • MEDI's Price/Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 27.38, MEDI is valued at the same level.
  • A Price/Forward Earnings ratio of 30.15 indicates a quite expensive valuation of MEDI.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDI indicates a slightly more expensive valuation: MEDI is more expensive than 66.67% of the companies listed in the same industry.
  • MEDI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.20.
Industry RankSector Rank
PE 26.87
Fwd PE 30.15
MEDI.OL Price Earnings VS Forward Price EarningsMEDI.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 60.32% of the companies in the same industry are cheaper than MEDI, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDI indicates a somewhat cheap valuation: MEDI is cheaper than 73.02% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 22.4
EV/EBITDA 19.23
MEDI.OL Per share dataMEDI.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDI does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of MEDI may justify a higher PE ratio.
PEG (NY)2.88
PEG (5Y)1.49
EPS Next 2Y10.32%
EPS Next 3Y10.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. MEDI.OL Dividend Analysis

5.1 Amount

  • MEDI has a Yearly Dividend Yield of 3.49%.
  • Compared to an average industry Dividend Yield of 1.23, MEDI pays a better dividend. On top of this MEDI pays more dividend than 92.06% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, MEDI pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.49%

5.2 History

  • The dividend of MEDI is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 68.76% of the earnings are spent on dividend by MEDI. This is not a sustainable payout ratio.
  • MEDI's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP68.76%
EPS Next 2Y10.32%
EPS Next 3Y10.81%
MEDI.OL Yearly Income VS Free CF VS DividendMEDI.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
MEDI.OL Dividend Payout.MEDI.OL Dividend Payout, showing the Payout Ratio.MEDI.OL Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDI.OL Fundamentals: All Metrics, Ratios and Statistics

MEDISTIM ASA

OSL:MEDI (4/16/2026, 3:54:35 PM)

234

+2 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-27
Earnings (Next)05-07
Inst Owners58.39%
Inst Owner ChangeN/A
Ins Owners0.07%
Ins Owner ChangeN/A
Market Cap4.29B
Revenue(TTM)699.77M
Net Income(TTM)159.21M
Analysts87.5
Price Target316.2 (35.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.49%
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DP68.76%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.57%
PT rev (3m)19.23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.65%
EPS NY rev (3m)-0.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9.67%
Revenue NY rev (3m)9.67%
Valuation
Industry RankSector Rank
PE 26.87
Fwd PE 30.15
P/S 6.13
P/FCF 22.4
P/OCF 22.4
P/B 9.16
P/tB 9.16
EV/EBITDA 19.23
EPS(TTM)8.71
EY3.72%
EPS(NY)7.76
Fwd EY3.32%
FCF(TTM)10.45
FCFY4.46%
OCF(TTM)10.45
OCFY4.46%
SpS38.16
BVpS25.54
TBVpS25.54
PEG (NY)2.88
PEG (5Y)1.49
Graham Number70.7477 (-69.77%)
Profitability
Industry RankSector Rank
ROA 24.1%
ROE 33.99%
ROCE 37.92%
ROIC 29.26%
ROICexc 49.58%
ROICexgc 49.58%
OM 28.04%
PM (TTM) 22.75%
GM 81.68%
FCFM 27.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-0.79%
OM growth 5Y1.29%
PM growth 3Y-0.6%
PM growth 5Y3.55%
GM growth 3Y1.4%
GM growth 5Y0.69%
F-Score7
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.2
Debt/EBITDA 0.18
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 90.27%
Profit Quality 120.33%
Current Ratio 3.34
Quick Ratio 2.21
Altman-Z N/A
F-Score7
WACC8.55%
ROIC/WACC3.42
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)104.92%
Profit Quality(5y)105.73%
High Growth Momentum
Growth
EPS 1Y (TTM)53.62%
EPS 3Y11.79%
EPS 5Y18.02%
EPS Q2Q%79.18%
EPS Next Y9.34%
EPS Next 2Y10.32%
EPS Next 3Y10.81%
EPS Next 5YN/A
Revenue 1Y (TTM)24.38%
Revenue growth 3Y12.46%
Revenue growth 5Y14.02%
Sales Q2Q%20.61%
Revenue Next Year18.2%
Revenue Next 2Y13.27%
Revenue Next 3Y11.61%
Revenue Next 5YN/A
EBIT growth 1Y49.68%
EBIT growth 3Y11.57%
EBIT growth 5Y15.49%
EBIT Next Year31.18%
EBIT Next 3Y16.67%
EBIT Next 5YN/A
FCF growth 1Y61.78%
FCF growth 3Y27.52%
FCF growth 5Y20.91%
OCF growth 1Y33.87%
OCF growth 3Y19.07%
OCF growth 5Y20.91%

MEDISTIM ASA / MEDI.OL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDISTIM ASA (MEDI.OL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to MEDI.OL.


Can you provide the valuation status for MEDISTIM ASA?

ChartMill assigns a valuation rating of 3 / 10 to MEDISTIM ASA (MEDI.OL). This can be considered as Overvalued.


What is the profitability of MEDI stock?

MEDISTIM ASA (MEDI.OL) has a profitability rating of 8 / 10.


Can you provide the expected EPS growth for MEDI stock?

The Earnings per Share (EPS) of MEDISTIM ASA (MEDI.OL) is expected to grow by 9.34% in the next year.


Is the dividend of MEDISTIM ASA sustainable?

The dividend rating of MEDISTIM ASA (MEDI.OL) is 6 / 10 and the dividend payout ratio is 68.76%.